BACKGROUND: Metabolic syndrome (MetS) is associated with an increased risk of coronary heart diseases and stroke. Results on the association of MetS with dementia and cognitive decline have been inconsistent. OBJECTIVE: The aim of this study was to examine the association between MetS and longitudinal changes in cognitive function. METHODS: Medline, EMBASE, and Scopus databases were searched from inception to June 2013. Longitudinal cohort studies that reported on the association between MetS and change in cognitive function (over two or more time points), were included. RESULTS: Random-effects models were used to assess the pooled effect sizes of longitudinal changes in cognitive function associated with MetS. Thirteen studies were included. The total sample size was 19,522 subjects. Follow up duration ranged from 1 to 16 years. In the total sample, a small association of MetS with cognitive decline was observed (SDM 0.06, 95%CI: -0.001, 0.12; p = 0.05). When age-stratified, a marginal significant association between MetS and cognitive decline was observed in the younger old group (≤70 years; SDM = 0.09, 95%CI: -0.003, 0.19; p = 0.05) but not in the older group (>70 years; SDM = 0.03, 95%CI: -0.05, 0.11; p = 0.48). The meta-regression showed that duration of follow up was not associated with changes in cognitive estimates (β = 0.005; p = 0.30). CONCLUSIONS: Age appears to modify the association between MetS and cognitive decline. These results emphasize the importance of age-stratified risk prediction models of dementia in subjects with chronic metabolic disorders.
BACKGROUND: Metabolic syndrome (MetS) is associated with an increased risk of coronary heart diseases and stroke. Results on the association of MetS with dementia and cognitive decline have been inconsistent. OBJECTIVE: The aim of this study was to examine the association between MetS and longitudinal changes in cognitive function. METHODS: Medline, EMBASE, and Scopus databases were searched from inception to June 2013. Longitudinal cohort studies that reported on the association between MetS and change in cognitive function (over two or more time points), were included. RESULTS: Random-effects models were used to assess the pooled effect sizes of longitudinal changes in cognitive function associated with MetS. Thirteen studies were included. The total sample size was 19,522 subjects. Follow up duration ranged from 1 to 16 years. In the total sample, a small association of MetS with cognitive decline was observed (SDM 0.06, 95%CI: -0.001, 0.12; p = 0.05). When age-stratified, a marginal significant association between MetS and cognitive decline was observed in the younger old group (≤70 years; SDM = 0.09, 95%CI: -0.003, 0.19; p = 0.05) but not in the older group (>70 years; SDM = 0.03, 95%CI: -0.05, 0.11; p = 0.48). The meta-regression showed that duration of follow up was not associated with changes in cognitive estimates (β = 0.005; p = 0.30). CONCLUSIONS: Age appears to modify the association between MetS and cognitive decline. These results emphasize the importance of age-stratified risk prediction models of dementia in subjects with chronic metabolic disorders.
Authors: Bronwen Martin; Rui Wang; Wei-Na Cong; Caitlin M Daimon; Wells W Wu; Bin Ni; Kevin G Becker; Elin Lehrmann; William H Wood; Yongqing Zhang; Harmonie Etienne; Jaana van Gastel; Abdelkrim Azmi; Jonathan Janssens; Stuart Maudsley Journal: J Biol Chem Date: 2017-05-18 Impact factor: 5.157
Authors: Paul L Wood; Srikanth Medicherla; Naveen Sheikh; Bradley Terry; Aaron Phillipps; Jeffrey A Kaye; Joseph F Quinn; Randall L Woltjer Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Caitlin N Pope; Jessica L Montoya; Elizabeth Vasquez; Josué Pérez-Santiago; Ronald Ellis; J Allen McCutchan; Dilip V Jeste; David J Moore; María J Marquine Journal: J Neurovirol Date: 2020-07-30 Impact factor: 2.643
Authors: Beverly Yu; Elizabeth Pasipanodya; Jessica L Montoya; Raeanne C Moore; Sara Gianella; Allen McCutchan; Ron Ellis; Robert K Heaton; Dilip V Jeste; David J Moore; María J Marquine Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Rasa Kazlauskaite; Imke Janssen; Robert S Wilson; Bradley M Appelhans; Denis A Evans; Zoe Arvanitakis; Samar R El Khoudary; Howard M Kravitz Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Hector M González; Wassim Tarraf; Priscilla Vásquez; Ashley H Sanderlin; Natalya I Rosenberg; Sonia Davis; Carlos J Rodríguez; Linda C Gallo; Bharat Thyagarajan; Martha Daviglus; Tasneem Khambaty; Jianwen Cai; Neil Schneiderman Journal: Diabetes Care Date: 2018-05-01 Impact factor: 19.112